Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Nucl Med Biol. 2009 Feb;36(2):147–153. doi: 10.1016/j.nucmedbio.2008.11.002

TABLE 3. Tissue distribution of activity of 18F-1.

Mean percent injected dose per gram ± SD (n = 5)
Tissue/organ 1 h 1 h (blocked)a 2 h 2 h (blocked)a
Blood 0.07 ± 0.01 0.05 ± 0.02 0.04 ± 0.01 0.04 ± 0.01
Lung 0.06 ± 0.01 0.06 ± 0.01 0.04 ± 0.02 0.04 ± 0.01
Liver 11.52 ± 3.80 8.36 ± 2.21 6.28 ± 1.89 5.51 ± 1.91
Spleen 0.13 ± 0.03 0.13 ± 0.03 0.07 ± 0.03 0.10 ± 0.04
Kidney 0.17 ± 0.05 0.14 ± 0.03 0.09 ± 0.02 0.08 ± 0.02
Muscle 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00
White Fat 0.05 ± 0.02 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00
Brown Fat 0.13 ± 0.01 0.07 ± 0.01 0.12 ± 0.03 0.08 ± 0.01
Heart 0.07 ± 0.01 0.06 ± 0.02 0.04 ± 0.01 0.04 ± 0.01
Bone 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.00 0.03 ± 0.01
a

Animals were cotreated with 15 μg of Farglitazar to block PPARγ mediated uptake.